**Supplemental Table 3. Top 10 Antibiotic Agents by Expenditures for Community, Non-Federal Hospitals, and Other Non-retail, 2010-2015** (expenditures are presented in millions).

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Antibiotic | 2010$\* (%) | 2011$\* (%) | 2012$\* (%) | 2013$\* (%) | 2014$\* (%) | 2015$\* (%) | Total Expenditures $\* (%) | P value\*\* |
| **Community** |  |  |  |  |  |  |  |  |
| Doxycycline | 0.79 (12.4) | 0.76(12.8) | 0.83(16.8) | 1.7 (30.5) | 1.3 (24.9) | 1.1 (21.9) | 6.5 (19.6) | 0.1023 |
| Minocycline | 0.79 (12.4) | 0.88 (15.0) | 0.66 (13.4) | 0.52 (9.1) | 0.41 (8.0) | 0.31 (6.4) | 3.6 (10.7) | 0.0223 |
| Levofloxacin | 1.3 (20.7) | 0.72 (12.2) | 0.04 (0.86) | 0.05 (0.91) | 0.04 (0.84) | 0.04 (0.82) | 2.2 (6.7) | 0.0363 |
| Amoxicillin / clavulanic acid | 0.46 (7.2) | 0.42 (7.1) | 0.34 (6.9) | 0.32 (5.6) | 0.45 (8.6) | 0.27 (5.5) | 2.3 (6.8) | 0.6384 |
| Azithromycin | 0.46 (7.2) | 0.41 (7.0) | 0.33(6.6) | 0.30 (5.2) | 0.31 (5.8) | 0.30 (6.3) | 2.1 (6.3) | 0.1418 |
| Tobramycin | 0.21 (3.3) | 0.23 (3.9) | 0.27 (5.6) | 0.33 (5.8) | 0.31 (6.0) | 0.25 (5.2) | 1.6 (4.8) | 0.0719 |
| Linezolid | 0.24 (3.7) | 0.25 (4.2) | 0.25 (5.1) | 0.27 (4.8) | 0.28 (5.4) | 0.47 (9.2) | 1.8 (5.3) | 0.0365 |
| Vancomycin | 0.24 (3.8) | 0.29 (4.9) | 0.32 (6.4) | 0.22 (3.8) | 0.15 (3.1) | 0.15 (3.3) | 1.4 (4.1) | 0.3667 |
| Cefdinir | 0.21 (3.3) | 0.21 (3.6) | 0.25 (5.0) | 0.31 (5.5) | 0.20 (3.7) | 0.16 (3.2) | 1.3 (4.0) | 0.9750 |
| Moxifloxacin | 0.34 (5.4) | 0.31 (5.3) | 0.21 (4.3) | 0.17 (3.0) | 0.05 (0.92) | 0.03 (0.58) | 1.1 (3.4) | 0.0013 |
| **Non-federal hospitals** |  |  |  |  |  |  |  |  |
| Piperacillin/ tazobactam | 0.65 (21.2) | 0.45 (16.0) | 0.40 (15.2) | 0.38 (15.2) | 0.39 (14.8) | 0.44 (16.4) | 2.7 (16.5) | 0.1922 |
| Daptomycin | 0.34 (11.0) | 0.42 (14.8) | 0.44 (16.9) | 0.46 (18.3) | 0.69 (25.8) | 0.64 (24.1) | 3.0 (18.1) | 0.0033 |
| Linezolid | 0.36 (11.6) | 0.37 (13.1) | 0.36 (13.6) | 0.35 (13.9) | 0.35 (13.2) | 0.21 (7.9) | 2.0 (12.1) | 0.4026 |
| Vancomycin | 0.16 (5.3) | 0.15 (5.3) | 0.14 (5.2) | 0.12 (4.7) | 0.13 (4.9) | 0.18 (6.6) | 0.87 (5.3) | 0.4502 |
| Ertapenem | 0.11 (3.6) | 0.12 (4.3) | 0.13 (5.1) | 0.13 (5.3) | 0.14 (5.1) | 0.16 (5.9) | 0.79 (4.8) | 0.0073 |
| Levofloxacin | 0.21 (6.9) | 0.17 (5.9) | 0.07 (2.6) | 0.06 (2.5) | 0.05 (1.9) | 0.04 (1.5) | 0.60 (3.6) | 0.0088 |
| Tigecycline | 0.13 (4.2) | 0.11 (4.1) | 0.11 (4.3) | 0.11 (4.2) | 0.07 (2.8) | 0.08 (2.8) | 0.61 (3.7) | 0.0506 |
| Meropenem | 0.12 (4.0) | 0.09 (3.2) | 0.10 (3.9) | 0.08 (3.0) | 0.08 (3.0) | 0.11 (3.9) | 0.58 (3.5) | 0.6725 |
| Aztreonam | 0.09 (3.1) | 0.09 (3.3) | 0.09 (3.5) | 0.09 (3.4) | 0.08 (3.1) | 0.08 (3.0) | 0.53 (3.2) | 0.5281  |
| Clindamycin | 0.06 (2.0) | 0.06 (2.3) | 0.07 (2.5) | 0.06 (2.3) | 0.05 (1.8) | 0.04 (1.6)  | 0.34 (2.1) | 0.2310 |
| **Other Non-retail** |  |  |  |  |  |  |  |  |
| Daptomycin | 0.12 (10.4) | 0.12(11.1) | 0.11 (12.9) | 0.11 (11.9) | 0.41 (35.3) | 0.43 (35.2) | 1.3 (20.0) | 0.0307 |
| Linezolid | 0.10 (8.8) | 0.11 (10.5) | 0.10 (11.9) | 0.11 (11.3) | 0.11 (9.3) | 0.09 (7.4) | 0.62 (9.5) | 0.4885 |
| Ertapenem | 0.06 (5.6) | 0.07 (6.7) | 0.08 (8.8) | 0.08 (8.9) | 0.10 (8.8) | 0.13 (10.4) | 0.52 (8.0) | 0.0060 |
| Vancomycin | 0.09 (7.7) | 0.08 (7.6) | 0.06 (7.6) | 0.05 (5.6) | 0.05 (4.4) | 0.06 (4.9) | 0.39 (6.1) | 0.0128 |
| Piperacillin/ tazobactam | 0.08 (7.5) | 0.07 (6.2) | 0.05 (6.0) | 0.05 (4.9) | 0.05 (4.0) | 0.05 (4.1) | 0.34 (5.3) | 0.0015 |
| Doxycycline | 0.02 (2.0) | 0.03 (2.5) | 0.02 (2.3) | 0.13 (13.6) | 0.10 (8.3) | 0.05 (3.8) | 0.34 (5.2) | 0.3899 |
| Levofloxacin | 0.15 (13.5) | 0.09 (8.5) | 0.01 (1.4) | 0.01 (1.2) | 0.009 (0.81) | 0.007 (0.61) | 0.28 (4.3) | 0.0252 |
| Meropenem | 0.05 (4.4) | 0.03 (2.9) | 0.02 (2.9) | 0.02 (2.3) | 0.02 (2.1) | 0.03 (2.3) | 0.18 (2.8) | 0.0303 |
| Tigecycline | 0.03 (2.8) | 0.03 (2.8) | 0.03 (3.6) | 0.03 (3.3) | 0.03 (2.3) | 0.03 (2.4) | 0.18 (2.7) | 0.4223 |
| Tobramycin | 0.03 (2.6) | 0.03 (2.8) | 0.03 (3.2) | 0.03 (3.0) | 0.03 (2.2) | 0.02 (1.6) | 0.16 (2.4) | 0.1718 |

\*Results are reported in $1,000,000s

\*\*P value is evaluating the trend in the proportion of expenditures over five years